

**Remarks/Arguments**

The Examiner indicated in the July 11, 2008 Office Communication that each claim had not been provided with the proper status identifier. In a subsequent telephone conversation with applicants' undersigned representative, Examiner Young stated that claims 18, 19, and 20 should be labelled "original" instead of "withdrawn." In response, applicants herein submit a substitute claim listing, in which the claim designations for claims 18 to 20 have been changed according to the Examiner's suggestion.

The above amendments have been made without prejudice to Applicants' right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101181-1P US

Although Applicants believe no other fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101181-1P US

Respectfully submitted,

/John X Haberman/

---

Name: John X Haberman  
Dated: August 8, 2008  
Reg. No.: 55,236  
Phone No.: 781-839-4736  
Global Intellectual Property, Patents  
AstraZeneca R&D Boston  
35 Gatehouse Drive  
Waltham, MA 02451